Navigation Links
GeoVax Labs, Inc. Announces Second Quarter Financial Results
Date:8/12/2011

ATLANTA, Aug. 12, 2011 /PRNewswire/ -- GeoVax Labs, Inc. (OTC BB: GOVX), an Atlanta-based, biopharmaceutical firm (the "Company") developing vaccines to prevent and fight Human Immunodeficiency Virus (HIV) infections, today announced its financial results and provided an operational update for the six months ended June 30, 2011.

GeoVax reported a net loss of $211,344 ($0.01 per share) for the three months ended June 30, 2011, compared to $933,089 ($0.06 per share) for the same period in 2010. For the six months ended June 30, 2011, the Company's net loss was $817,626 ($0.05 per share) as compared to $1,623,878 ($0.10 per share) in 2010.  Net losses were partially offset by revenues related to the Company's grant from the NIH in support of the its HIV/AIDS vaccine development activities; such revenues were $1,753,033 and $2,646,035 for the three month and six month periods of 2011, respectively, as compared to $1,737,169 and $3,075,729 for the three month and six month periods of 2010, respectively.  As of June 30, 2011, the Company reported cash balances totaling $668,055, as compared to $1,079,087 at December 31, 2010.

GeoVax President and CEO Robert T. McNally, PhD, commented, "While the continued progress of our clinical development programs remains our priority, financing efforts have represented a major activity during the last quarter.  Our current cash balances, together with anticipated proceeds from our NIH grant, are sufficient to support our planned operations into 2012.  Although current market conditions present a challenging environment, we remain confident that we will achieve the funding necessary to advance our vaccine development programs."

Dr. McNally continued, "Our opening the Los Angeles, AIDS Research Alliance (ARA) site, has added to the number of individuals currently being stabilized on conventional oral medications in preparation for vaccination in our Phase 1 therapeutic trial.  A stabilization period is necessary before individuals can be vaccinated.  ARA joins two other clinics, the AIDS Research Consortium of Atlanta and the University of Alabama at Birmingham, as clinical sites to test safety and the ability of our vaccine to control the HIV virus in HIV-positive individuals."

GeoVax's Chairman of the Board David Dodd further commented, "During the last quarter, GeoVax strengthened its financial, operational and technical support ties with the NIH and the HIV Vaccine Trials Network (HVTN).  The clinical path forward with our vaccine is very clear as we benefit from NIH encouragement and HVTN planning for a Phase 1 clinical trial incorporating the GM-CSF adjuvanted version of the vaccine which achieved 70% protection against simian immunodeficiency virus (SIV) infection in nonhuman primates.  This trial, depending on FDA submission schedules, is anticipated to commence within the next six months.  In addition, GeoVax has already made progress with the HVTN committee, planning necessary to implement the next clinical level Phase 2b efficacy trial using the Company's impressive technology."

Summarized financial information is presented below.  Further information concerning the Company's financial position and results of operations is included in its Quarterly Report on Form 10-Q to be filed with the Securities and Exchange Commission.

About GeoVax Labs, Inc.GeoVax is a biotechnology company developing human vaccines for diseases caused by HIV.  Our goals include developing HIV/AIDS vaccines for global markets, overseeing the manufacture and testing of these vaccines under GMP/GLP conditions (FDA guidelines), conducting clinical trials for vaccine safety and effectiveness, and obtaining regulatory approvals to move the product forward.  GeoVax's vaccines are unique in expressing virus like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein.  All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of our DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as, the vaccines' safety.  Successful results from Phase 1 testing supported the initiation of the first Phase 2 testing. GeoVax's Phase 2 human trial began in January 2009 and will ultimately involve 300 participants at sites in the United States and South America.  Recently GeoVax began enrolling patients in a Phase 1 therapeutic trial for individuals already infected with HIV.  For more information, please visit www.geovax.com.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.  GeoVax assumes no obligation to update these forward-looking statements, and does not intend to do so.  More information about these factors is contained in GeoVax's filings with the Securities and Exchange Commission including those set forth at "Risk Factors" in GeoVax's Form 10-K.

Contact:The Investor Relations Group
Erika Moran, Investor Relations
Janet Vasquez, Public Relations
(212) 825-3210GEOVAX LABS, INC.Condensed Consolidated Statements of Operations Information(amounts in thousands, except per share data)Three Months Ended

Six Months EndedJune 30,

June 30, 2011

2010

2011

2010RevenuesGrant Revenue$  1,753

$  1,737

$  2,646

$  3,076Operating expenses:Research and development1,386

1,742

2,224

3,111General and administrative579

936

1,241

1,6051,965

2,678

3,465

4,716Other income:Interest income1

8

1

161

8

1

16Net loss$  (211)

$  (933)

$  (818)

$  (1,624)Income (loss) per common share$  (0.01)

$  (0.06)

$  (0.05)

$  (0.10)GEOVAX LABS, INC.Condensed Balance Sheet Information(amounts in thousands)June 30,

Dec. 31,2011

2010Assets:Cash and cash equivalents$
8

$
,079Other current assets680

523Total current assets1,348

1,602Property, net 206

249Other assets580

507Total assets$
2,134

$
2,358Liabilities and stockholders' equityCurrent liabilities$
730

$
522Stockholders' equity1,404

1,836Total liabilities and stockholders' equity$
2,134

$  2,358Shares Outstanding15,752

15,655
'/>"/>

SOURCE GeoVax Labs, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GeoVax Successful HIV/AIDS Vaccine Trial Data Presented at AIDS Vaccine 2007 Conference
2. GeoVax Labs, Inc. Comments on Discontinuance of Mercks HIV Vaccine Trial
3. Excellent Results Received from GeoVaxs Full-Dose HIV/AIDS Vaccine Trial
4. GeoVax Labs, Inc. Third Quarter Financial Results and Operational Update
5. GeoVax Labs, Inc. Selects Financial Relations Board as Investor Relations Counsel
6. GeoVax Labs, Inc. Selected by Georgia Bio as 2008 Deal of the Year Award Winner in Life Sciences Industry
7. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
8. GeoVax Vaccine Only 5th AIDS Vaccine Moving to Phase 2 Human Trials
9. GeoVax Labs, Inc. Reports Fourth Quarter and Year-End 2007 Financial Results
10. GeoVax Secures $10 Million Financing Commitment
11. GeoVax Reports Progress on Its AIDS Vaccine Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray ... showcase a healthy CAGR during the forecast period ... in the global digital mobile X-Ray devices market, which is ... in 2017, expanding at a CAGR of 7% over the ... $ opportunity of more than US$ 100 Mn in 2017 ...
(Date:4/19/2017)... The Global Effective Microorganisms (EM) Market ... has covered and analysed the potential of Global Effective Microorganisms ... shares and growth factors. The report identifies and analyses the ... the global market. ... 152 Tables and Figures, 6 Major Company Profiles, spread across ...
Breaking Medicine Technology:
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... solutions, announces the continuation of its strategic partnership with and platinum sponsorship of ... nations in the safe and effective management of complex spine deformity cases, particularly ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... Bring Your Own Device (BYOD) capabilities at Telehealth 2.0, the American Telemedicine Association’s ... bundles, which pairs medical devices with a pre-programmed tablet in a remarkably easy-to-use ...
(Date:4/24/2017)... ... 24, 2017 , ... The Santana Telehealth Project was honored with the 2017 ... American Telemedicine Association’s annual conference, on April 23 in Orlando, FL. , “I am ... the lives of the poor and underserved in other parts of the world,” said ...
(Date:4/24/2017)... TX (PRWEB) , ... April 24, 2017 , ... As ... Memorial Museum today to honor the victims of the Holocaust and Nazi persecution, ... ceremonies at Hadamar and Auschwitz on its CMATH Champions trip to Germany and Poland ...
Breaking Medicine News(10 mins):